Literature DB >> 11360928

Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo.

D Frleta1, D Demian, W F Wade.   

Abstract

We examined the efficacy of using monoclonal antibodies to target antigen (avidin) to different surface molecules expressed on antigen presenting cells (APC). In particular, we targeted CD40 to test whether the "adjuvant" properties of CD40 signaling combined with targeted antigen would result in enhanced serologic responses. We targeted avidin to class II as a positive control and to CD11c as a negative control. These surface proteins represent an ensemble of surface molecules that signal upon ligation and that are expressed on professional APC, in particular dendritic cells (DC). We observed that targeting class II molecules on APC was superior to targeting CD40, or CD11c. However, CD40 and CD11c could function as targets for antigen bound monoclonal antibodies under certain conditions. Interestingly, inclusion of anti-CD40 mAb with the targeting anti-class II-targeted antigens negatively affects humoral response, suggesting that CD40 signaling under certain conditions may suppress processing and/or presentation of targeted antigen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11360928     DOI: 10.1016/s1567-5769(00)00032-1

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

1.  Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: modulation of serologic response, epitope specificity, and isotype.

Authors:  J Y Wu; R K Taylor; W F Wade
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 2.  Dendritic cell-targeted vaccines--hope or hype?

Authors:  Wolfgang Kastenmüller; Kathrin Kastenmüller; Christian Kurts; Robert A Seder
Journal:  Nat Rev Immunol       Date:  2014-09-05       Impact factor: 53.106

3.  Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant.

Authors:  Ann L White; Alison L Tutt; Sonya James; Kevin A Wilkinson; Fernanda V V Castro; Sandra V Dixon; Jessica Hitchcock; Mahmood Khan; Aymen Al-Shamkhani; Adam F Cunningham; Martin J Glennie
Journal:  Immunology       Date:  2010-05-10       Impact factor: 7.397

4.  Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection.

Authors:  Sudeep Kumar; Raju Sunagar; Edmund J Gosselin
Journal:  Vaccines (Basel)       Date:  2020-04-23

5.  Haemagglutinin antigen selectively targeted to chicken CD83 overcomes interference from maternally derived antibodies in chickens.

Authors:  Angita Shrestha; Rick Meeuws; Jean-Remy Sadeyen; Pengxiang Chang; Marielle Van Hulten; Munir Iqbal
Journal:  NPJ Vaccines       Date:  2022-03-03       Impact factor: 9.399

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.